Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IRI workforce reduction

This article was originally published in The Tan Sheet

Executive Summary

Market researcher announces plans to cut about 5% of its workforce in the U.S. and Europe through layoffs and elimination of open positions. Move will result in $7.8 mil. pre-tax charge in the fourth quarter, which will cause firm to miss 2002 earnings target, IRI says. Layoffs are intended to reduce costs related to company's retail tracking business and allow for greater investment in opportunities including expanded channel coverage, according to firm. IRI Q3 revenues increased 2% to $140.6 mil., as a 5% decline in retail tracking revenues was offset by an 18% gain in panel and analytic products and services. Net income was $900,000, compared to a $500,000 loss in prior-year period...

You may also be interested in...



IRI on sales block?

Information Resources, Inc. shareholder Chap-Cap Partners pressures Chairman, CEO & President Joseph Durrett in Feb. 13 letter to "sell the company to the highest bidder" before "IRI's shareholders take it upon themselves to find another CEO and board of directors who will do so in your stead." El Segundo, Calif.-based investment group has collected a 5.6% stake in the market research firm since Jan. 8, shortly after Procter & Gamble announced plans to terminate its contract with IRI (1"The Tan Sheet" Dec. 16, 2002, In Brief). IRI reported flat worldwide revenues of $554.8 mil. in 2002 and a $13 mil. net loss, which followed a $3.9 mil. deficit the prior year...

Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow

FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.

Advanced Imaging Group Calls For Swifter FDA Approvals For Mobile X-Ray, CT, Ultrasound Devices For COVID-19 Crisis

The Medical Imaging & Technology Alliance (MITA) recently sent a letter to the US FDA recommending steps the agency can take to help the advanced imaging industry quickly respond to the COVID-19 outbreak.

Topics

UsernamePublicRestriction

Register

PS094906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel